Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 2012. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a capital structure notification rather than a financial performance report.
Material Changes
The filing details the Company's issued share capital as of June 29, 2012:
- Total Issued Shares: 5,467,489,920 Ordinary Shares of 25p each.
- Treasury Shares: 475,557,927 Ordinary Shares held in Treasury.
- Total Voting Rights: 4,991,931,933.
The filing does not explicitly state material changes compared to a prior comparable period, though it provides the definitive denominator for shareholder notification calculations.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly limited to the notification of share capital and voting rights.
Investor Verification Checklist
- Verify the total number of voting rights (4,991,931,933) for compliance with Financial Services Authority disclosure thresholds.
- Confirm the number of shares held in Treasury (475,557,927) to calculate the net outstanding share count.
- Review the Company's Form 20-F for comprehensive financial performance data, as this 6-K does not contain financial results.